Releases
NEO
14.03
-0.92%
-0.13
  • All
  • Financials
  • Insiders
More
Webull provides the latest Neogenomics Inc (NEO) stock and general news. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.